Nausea & Vomiting | Lymphoma Research | COVID-19 & Trials, Cancer Information Highlights, June 24, 2020

Nausea & Vomiting | Lymphoma Research | COVID-19 & Trials, Cancer Information Highlights, June 24, 2020

Cancer Information Highlights From the National Cancer Institute Updating you about cancer causes, prevention, screening, treatment, coping, and more   New from NCI Olanzapine Reduces Nausea and Vomiting   Scientists may have found a treatment for people with advanced cancer who have nausea and vomiting that is not caused by chemotherapy. Learn more about the study that led to this finding. Advances in Lymphoma Research   NCI-funded researchers are working to advance our knowledge of how to treat lymphoma. Learn more about the types of lymphoma and the many treatment advances that have been made. Cancer Clinical Trials during COVID-19 The coronavirus has forced some changes to cancer clinical trials. Read how COVID-19 has affected some NCI trials and what patients in these trials should know. Infographic—What is SEER?   This infographic helps explain SEER, NCI’s program to track cancer cases and deaths caused by different cancers in the United States. Data from this program show trends that help inform future research efforts. Two Targeted Therapy Drugs Approved for Prostate Cancer Two recent approvals by the Food and Drug Administration (FDA) offer some men with prostate cancer a new way to treat their cancer: targeted therapy. Read more about these drugs, which target certain genetic changes that prevent cells from repairing damage to their DNA. Selpercatinib Approved for Certain Thyroid and Lung Cancers People with thyroid or lung cancer whose tumors contain specific changes in a gene called RET now have a new treatment option. Learn more about how changes in the RET gene cause cancer and how this drug works against cancers with these changes. FDA Approvals Nivolumab We’ve updated our drug summary on nivolumab (Opdivo). FDA recently approved it to treat patients with squamous cell carcinoma of the esophagus that cannot be removed by surgery and has either spread to other parts of the body or come back after treatment. Pembrolizumab We’ve updated our drug summary on pembrolizumab (Keytruda). Pembrolizumab is now approved by FDA to treat certain patients with non-small cell lung cancer whose tumors have the PD-L1 protein. Pembrolizumab was also recently approved to treat adults and children with solid tumors that have a high number of genetic changes and cannot be removed by surgery.   Also of Interest Cancer Biology Research Research on cancer biology is vital to progress against the disease. Learn more about the challenges, opportunities, and NCI’s role in this area of research. Coronavirus and Cancer Many people with cancer have questions about coronavirus. This new web page presents information about coronavirus and COVID-19, including: what patients with cancer should know about the virus how the disease may affect their cancer care research studies for people with cancer and COVID-19 news about NCI’s response to COVID-19